These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 7610630)

  • 1. [The effect of experimental therapy on lymphocyte dehydrogenase activity in the peripheral blood of rats with ascitic ovarian tumors].
    Sheĭko EA; Pil' EA
    Vopr Onkol; 1994; 40(7-12):327-31. PubMed ID: 7610630
    [No Abstract]   [Full Text] [Related]  

  • 2. [Coordination of lymphocytic enzymes of the rat thymus gland in experimental chemotherapy].
    Sheĭko EA; Pil' EA
    Vopr Onkol; 1994; 40(4-6):207-10. PubMed ID: 7785246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Isoenzymes of lactate dehydrogenase in ovarian carcinoma].
    Jung G; Kidess E; Closs A; Unbehaun V
    Med Welt; 1967 Dec; 51():3112-5. PubMed ID: 5608862
    [No Abstract]   [Full Text] [Related]  

  • 4. [Energy metabolism of blood lymphocytes after insertion of titanium implants].
    Saranchina EB; Loginov AG; Gorchakov VN
    Morfologiia; 2003; 123(1):55-8. PubMed ID: 12741112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.
    Colombo N; Formelli F; Cantù MG; Parma G; Gasco M; Argusti A; Santinelli A; Montironi R; Cavadini E; Baglietto L; Guerrieri-Gonzaga A; Viale G; Decensi A
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1914-9. PubMed ID: 17035399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor cell origin of histaminase activity in ascites fluid from patients with ovarian carcinoma.
    Ettinger DS; Rosenshein NB; Parmley TH; Mendelsohn G; Baylin SB
    Cancer; 1980 May; 45(10):2568-72. PubMed ID: 6769580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytogenetic damage in lymphocytes of patients undergoing therapy for small cell lung cancer and ovarian carcinoma.
    Padjas A; Lesisz D; Lankoff A; Banasik A; Lisowska H; Bakalarz R; Góźdź S; Wojcik A
    Toxicol Appl Pharmacol; 2005 Dec; 209(2):183-91. PubMed ID: 15885733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.
    Chen YJ; Yuan CC; Chow KC; Wang PH; Lai CR; Yen MS; Wang LS
    Gynecol Oncol; 2005 Apr; 97(1):110-7. PubMed ID: 15790446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Differences in the composition of cellular elements of blood and lymphocyte dehydrogenase activity in rats with genetic variability in neuroendocrine status].
    Griazeva NI; Robinson MV; Barykina NN; Shurlygina AV; Kolpakov VG; Trufakin VA
    Biull Eksp Biol Med; 1998 May; 125(5):555-7. PubMed ID: 9644558
    [No Abstract]   [Full Text] [Related]  

  • 10. Experimental and clinical evaluation of cisplatin-containing microspheres as intraperitoneal chemotherapy for ovarian cancer.
    Sugiyama T; Kumagai S; Nishida T; Ushijima K; Matsuo T; Yakushiji M; Hyon SH; Ikada Y
    Anticancer Res; 1998; 18(4B):2837-42. PubMed ID: 9713471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Nucleic factor in the ascitic fluid in human ovarian tumors].
    Zelenkova NK; Belokhvostov AS; Lipova VA; Aĭnbinder NM
    Vopr Onkol; 1980; 26(8):45-8. PubMed ID: 7415050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Assessment of antineoplastic action of dehydrogenases in peripheral blood lymphocytes in S-45 tumor-bearing rats exposed to weak ultra-low-frequency irradiation].
    Shiikhliarova AI; Sheĭko EA; Pil' EA
    Vopr Onkol; 1999; 45(3):287-91. PubMed ID: 10443233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme histochemistry of experimental ovarian tumors in mice.
    Ueda G; Hayakawa K; Hamanaka N; Yoshinare S; Sato Y; Okudaira Y
    Acta Obstet Gynaecol Jpn; 1972 Jan; 19(1):16-24. PubMed ID: 4678775
    [No Abstract]   [Full Text] [Related]  

  • 14. Peritoneal fluid lactate dehydrogenase in ovarian cancer.
    Schneider D; Halperin R; Langer R; Bukovsky I; Herman A
    Gynecol Oncol; 1997 Sep; 66(3):399-404. PubMed ID: 9299252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphocytes isolated from the peritoneal fluid of women with advanced ovarian carcinoma differ significantly from autologous peripheral blood lymphocytes.
    Melioli G; Ferrari I; Casartelli G; Ragni N
    Gynecol Oncol; 1993 Mar; 48(3):301-7. PubMed ID: 8462898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of purified glutaminase from human ascites fluid on experimental tumor bearing mice.
    Bhattacharya P; Sett S; Maity P
    J Exp Clin Cancer Res; 2001 Dec; 20(4):599-607. PubMed ID: 11876557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concluding remarks: optimal treatment for women with ovarian cancer.
    Trimble EL
    Semin Oncol; 2006 Dec; 33(6 Suppl 12):S25-6. PubMed ID: 17223447
    [No Abstract]   [Full Text] [Related]  

  • 18. Chemotherapy delivered into abdomen may extend ovarian cancer survival.
    Mayo Clin Womens Healthsource; 2006 Jun; 10(6):3. PubMed ID: 16675917
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical relevance of matrix metalloproteinase-13 determined with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients.
    Hantke B; Harbeck N; Schmalfeldt B; Claes I; Hiller O; Luther MO; Welk A; Kuhn W; Schmitt M; Tschesche H; Muehlenweg B
    Biol Chem; 2003 Aug; 384(8):1247-51. PubMed ID: 12974393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors.
    van der Zee AG; de Jong S; Keith WN; Hollema H; Boonstra H; de Vries EG
    Cancer Res; 1994 Feb; 54(3):749-55. PubMed ID: 8306337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.